NFL Biosciences
France - MontpellierBiotechnology
Focus: NFL Biosciences is a newly founded (2023) French biotech company focused on developing botanical drugs for smoking cessation, operating from Montpellier with an undisclosed team size.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About NFL Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow NFL Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NFL-101 dose 1
Smoking CessationClinical Trials (1)
NCT04571216Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy
Phase 2Help build intelligence for NFL Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.